Genesis and biology of vestibular schwannomas

Progress in Neurological Surgery

Volumn 21, Issue , 2008, Pages 24-31

  Roche, Pierre Hugues ^a   Bouvier, Corinne ^b   Chinot, Olivier ^b   Figarella Branger, Dominique ^b  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MERLIN;

GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NEUROFIBROMATOSIS; NEUROMA; PATHOLOGY; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

EPIGENESIS, GENETIC; GENES, NEUROFIBROMATOSIS 2; HUMANS; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; NEUROMA, ACOUSTIC;

EID: 58149398485     PISSN: 00796492     EISSN: 16623924     Source Type: Book Series    
DOI: 10.1159/000156556     Document Type: Review

References (43)

1. Neely JG, Britton BH, Greenberg SD: Microscopic characteristics of the acoustic tumor in relationship of its nerve of origin. Laryngoscope 1976;86:984-991.
2. th nerve of man. J Laryngol Otol 1980;94:1353-1362.
3. Foncin JF, Sterkers JM, Perre J, Cor-lieu P: The origin of acoustic neuroma. An ultrastructural study of operated neurinoma incipiens. Ann Otolaryngol Chir Cervicofac 1979;96:11-22.
4. Pirsig W, Eckermeier L, Mueller D: As to the origine of vestibular schwan-nomas; in House WF (ed): Acoustic Tumors. Vol 1-diagnosis. Baltimore: University Park Press, 1979, pp 52-55.
5. Boutin P, Guth A, Bouccara D, El Garem H, Rey A, Sterkers O: Intralaby-rinthine schwannomas: a report of two cases. Ann Otolaryngol Chir Cer-vicofac 1998;115:35-41.
6. Tos M, Drozdziewicz D, Thomsen J: Medial acoustic neuromas. A new clinical entity. Arch Otolaryngol Head Neck Surg 1992;118:127-133.
7. Lanser MJ, Sussman SA, Frazer K: Epidemiology, pathogenesis, and genetics of acoustic tumors. Otolaryn-gol Clin North Am 1992;25:499-520.
8. Seizinger BR, Martuza RL, Gusella JF: Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 1986;322:644-647.
9. Wertelecki W, Rouleau GA, Super-neau DW, Forehand LW, Williams JP, Haines JL, Gusella JF: Neurofibroma-tosis 2:Clinical and DNA linkage studies of a large kindred. N Engl J Med 1988;319:278-283.
10. Tsukita S, Oioshi K, Sato N, Sagara J, Kawai A: ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytosqueletons. J Cell Biol 1994;126:391-401.
11. + exchange, is a common interactor for Merlin and ERM (MERM) proteins. J Biol Chem 1998;273:1273-1276.
12. Gutmann DH: The neurofibroma-toses: when less is more. Hum Mol Genet 2001;10:747-755.
13. Xu HM, Gutmann DH: Merlin differentially associates with the microtu-bules and actin cytoskeleton. J Neurosci Res 1998;51:403-415.
14. Gutmann DH, Sherman L, Seftor L, et al: Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Hum Mol Genet 1999;8:267-275.
15. Fuks F: DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 2005;15: 490-495.
16. Gonzalez-Gomez P, Bello MJ, Alonso ME, Lomas J, Arjona D, de Campos JM, Vaquero J, Isla A, Lassaletta L, Gutierrez M, Sarasa JL, Rey JA: CpG Island Methylation in sporadic and Neurofibromatosis Type 2-Associated schwannomas. Clin Res Cancer 2003;9:5601-5606.
17. Kim JY, Kim H, Jeun SS, Rha SS, Kim YH, Ko YJ, Won J, Lee KH, Rha HK, Wang YP: Inhibition of NF-kB activation of merlin. Biochem Biophys Res Commun 2002;296:1295-1302.
18. Schulze KM, Hanemann CO, Müller HW, Hanenberg H: Transduction of wild-type merlin into human schwannoma cells decreases schwan-noma cell growth and induces apop-tosis. Hum Mol Genet 2002;11:69-76.
19. Scoles DR, Nguyen VD, Qin Y, Sun CX, Morrison H, Gutmann DH, Pulst SM: Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its interacting protein HRS regulate STAT signaling. Hum Mol Genet 2002;11:3179-3189.
20. Fraenzer JT, Pan H, Minimo L, Smith GM, Knauer D, Hung G: Overexpres-sion of the NF2 gene inhibits schwan-noma cell proliferation through promoting PDGFR degradation. Int J Oncol 2003;23:1493-1500.
21. Sherman LS, et al: Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997;15:2505-2509.
22. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan J P, Gupta V, Ratner N, Der CJ, Jacks T, McClatchey AL: The Nf2 tumor suppressor, merlin, functions in Rac-de-pendent signaling. Dev Cell 2001;1:63-72.
23. Rong R, Surace EI, Haipek CA, Gutmann DH, Ye K: Serine 518 phos-phorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 2004;23:8447-8454.
24. Sherman LS, Gutmann DH, Merlin: Hanging tumor suppression on the Rac. Trends Cell Biol 2001;11: 442-444.
25. Surace EI, Haipek CA, Gutmann DH: Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene 2004;15:580-587.
26. Cushing H: Tumor of the nervus acousticus and the syndrome of the cerebellopontine angle. 1917.
27. Matthies C, Samii M: Management of 1000 vestibular schwannomas: clinical presentation. Neurosurgery 1997;40:1-9.
28. Kazantikul V, Brown WJ: Oestrogen receptors in acoustic neurilemmo-mas. Surg Neurol 1981;15:105-109.
29. Markwalder TM, Waelti E, Mark-walder RV: Estrogen and progesterone receptors in acoustic and spinal neurilemmomas. Clinicopathologic correlations. Surg Neurol 1986;26: 142-148.
30. Carroll RS, Zhang JP, Black PM: Hormone receptors in vestibular schwan-nomas. Acta neurochir 1997;1139: 188-193.
31. Bartolami S, Auge C, Travo C, Venteo S, Knipper M, Sans A: Vestibular schwann cells are a distinct subpopulation of peripheral glia with specific sensitivity to growth factors and extracellular matrix components. J Neurobiol 2003;57:270-290.
32. Caye-Thomasen P, Baandrup L, Ja-cobsen GK, Thomsen J, Stangerup SE: Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 2003;113:2129-2134.
33. Sturgis EM, Woll SS, Aydin F, Mar-rogi AJ, Amedee RG: Epidermal growth factor receptor expression by acoustic neuromas. Laryngoscope 1996;106:457-462.
34. Antoni NRE: Über Rückenmarkstumoren und neurofibroma. Kommissions-Verlag von J.F. Bergmann, Munich, 1920, pp 234-311.
35. Curto M, Chan A, Cole B, McClathey AI: The role of Merlin and the ERM proteins in membrane organization. International workshop on neurofi-bromatosis type 2, Paris, 2006.
36. Gentry JJ, Casaccia-Bonnefil P, Carter BD: Nerve growth factor activation of nuclear factor kB through its p75 receptor is an anti-apoptotic signal in RN22 schwannoma cells. J Biol Chem 2000;275:7558-7565.
37. Welling DB, Lasak JM, Akhmametye-va E, Ghaheri B, Chang LS: CDNA microarray analysis of vestibular schwannomas. Otol Neurotol 2002;23:736-748: 403-415.
38. Warren C, James LA, Ramsden RT, Wallace A, Baser ME, Varley JM, Evans DG: Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridization. J Med Genet 2003;40:802-806.
39. Sherr CJ: The Pezcoller lecture: Cancer cell cycle revisited. Cancer Res 2000;60:3689-3695.
40. Lasak JM, Welling B, Akhmametyeva EM, Salloum M, Chang LS: Retino-blastoma-Cyclin-Dependent kinase pathway deregulation in vestibular schwannomas. Laryngoscope 2002; 112:1555-1561.
41. Kato M, Wilmotte R, Belkouch MC, de Tribolet N, Pizzolato G: Survivin in brain tumors: an attractive target for immunotherapy. J Neurooncol 2003;64:71-76.
42. Mawrin C, Kirches E, Dietzmann K, Roessner A, Boltze C: Expression pattern of apoptotic markers in vestibu-lar schwannomas. Pathol Res Pract 2002;198:813-819.
43. Kimura Y, Koga H, Araki N, Mugita N, Fujita N, Takeshima H, Nishi T, Yamashima T, Saido TC, Yamasaki T, Moritake K, Saya H, Nakao M: The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nat Med 1998;4: 915-922.